[NEW YORK] 8th Jan 2020 – DeckTherapeutics Inc today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15th, during the most important week in healthcare at the Hilton San Francisco Union Square.
Suman Lal, MD PhD (CEO) will be presenting DeckTherapeutics at Biotech Showcase as follows:
Date: TUESDAY, January 14, 2020
Time: 10:45AM (PST)
Room: Franciscan C (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
DeckTherapeutics will present the company’s technology and current clinical development plan of THDG3, a novel patent protected omega-3 fatty acid lipid emulsion as an acute treatment for ischemic stroke. THDG3 has an improved pharmacokinetic profile leading to activation of cellular pathways within 20-30 min of IV administration. The pleotropic/multiple omega-3 neuroprotective pathways results in up to 90% reduction in brain infarct size in pre-clinical stroke models with preservation of neurological function, together with a wide therapeutic window.
“The recent strongly positive results of the REDUCE-IT trial, has led to a renewed enthusiasm for using omega-3 fatty acids to prevent and treat cardiovascular diseases. We are also now transitioning into a new era of acute omega-3 therapeutics, as against traditional chronic supplementation approaches. These developments are opening up new treatment scenarios and clinical benefits for patients”, said Dr Richard Deckelbaum, a Professor at Columbia University and also the Founding Scientist and Chair of the Scientific Advisory Board at DeckTherapeutics.
“With the new and now available imaging modalities that allow selection of homogeneous group of patients with an ischemic penumbra, and understandings around re-perfusion injuries in ischemic stroke, the field of stroke pharmacotherapy is entering into novel domains, potentially leading to cures for the largest unmet need in medicine and long-term disability today.” said Dr Suman Lal, CEO of DeckTherapeutics.
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
“We are delighted that DeckTherapeutics will be presenting its product at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
ABOUT BIOTECH SHOWCASE
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 12th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
ABOUT DECKTHERAPEUTICS INC
DeckTherapeutics Inc is an 'acute omega-3 fatty acid therapeutics' company developing treatments for stroke and other acute organ injuries. The science behind DeckTherapeutics originated at the laboratory of Dr. Richard Deckelbaum, Director of the Institute of Human Nutrition, Robert R. Williams Professor of Nutrition and Professor of Pediatrics and of Epidemiology at Columbia University, New York.
Contacts
SUMAN LAL (suman@decktherapeutics.com)
RICHARD DECKELBAUM (rjd@decktherapeutics.com)
